Conditions: Multiple Sclerosis
Keywords: Multiple Sclerosis Relapsing-Remitting
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 162
Healthy volunteers: no

Brief summary:
This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient population that closely resembles the clinical population seen in routine medical care.

Detailed description:

Arms:
arm 1: Open-label fingolimod 0.5 mg, taken orally once daily for 4 months

Interventions: intervention 1: Fingolimod
Intervention descriptions: intervention 1: Fingolimod will be supplied as 0.5mg capsules in bottles of 35.

Protocol document: